ME VS CDNA Stock Comparison
Performance
ME10/100
10/100
ME returned -75.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
CDNA10/100
10/100
CDNA returned -51.38% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.
Technicals
ME36/100
36/100
ME receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
CDNA64/100
64/100
CDNA receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
ME10/100
10/100
ME has missed earnings 5 times in the last 20 quarters.
CDNA10/100
10/100
CDNA has missed earnings 7 times in the last 20 quarters.
Profit
ME10/100
10/100
Out of the last 14 quarters, ME has had 0 profitable quarters and has increased their profits year over year on 0 of them.
CDNA10/100
10/100
Out of the last 20 quarters, CDNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
ME45/100
45/100
ME has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
CDNA35/100
35/100
CDNA has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.
Analyst Price Targets
ME
"Analyst Price Targets" not found for ME
CDNA75/100
75/100
3 analysts offer 12-month price targets for CDNA. Together, they have an average target of 39.5, the most optimistic target put CDNA at 50 within 12-months and the most pessimistic has CDNA at 29.
Sentiment
ME
"Sentiment" not found for ME
CDNA70/100
70/100
CDNA had a bullish sentiment score of 69.57% across Twitter and StockTwits over the last 12 months. It had an average of 4.90 posts, 0.70 comments, and 3.40 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
23andMe Holding Co. Class A Common Stock Summary
Nasdaq / ME
Healthcare
Medical - Diagnostics & Research
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
CareDx, Inc. Summary
Nasdaq / CDNA
Healthcare
Medical - Diagnostics & Research
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ME to other companies in the same or a similar industry.